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Lycopodium clavatum as an inhibitor of monosodium urate crystallisation in
gout: An in vitro study
Abstract
Background
Background: Hyperuricaemia plays a significant role in the development and pathogenesis of several
metabolic and systemic disorders including metabolic syndrome, hypertension, stroke and
atherosclerosis. Lycopodium clavatum is the most widely used drug in homoeopathy for treating
hyperuricaemia and gout. However, its mechanism of action in reducing serum uric acid remains
uncertain. Objective
Objective: The objective of the study was to study the potential role of homoeopathic
preparation of Lycopodium clavatum in different potencies on monosodium urate crystallisation in vitro.
Methods
Methods: Spectrophotometric crystallisation assay was carried out on a stock solution of 5 ml of uric
acid after its preparation. The time course of the optical density was measured in a standard solution and
values were measured every 5 min after agitation with cyclo-vortex mixer. The optical density values were
also measured in the homoeopathic preparation of Lycopodium clavatum in different potencies with
same method. Inhibiting effect of this medicine was found from graphs by measuring slope of nucleation
and aggregation from optical density value and the percentage inhibition exerted by the proteins was
calculated. Results
Results: Spectrophotometric analysis showed all potencies of Lycopodium clavatum inhibited
aggregation of monosodium urate crystals with a maximum inhibition at 200C and 1M potency.
Conclusion
Conclusion: We found that the homoeopathic medicine Lycopodium clavatum could be effective in
inhibiting the formation of monosodium urate crystals in vitro and also causes the dissolution of crystals,
especially in high potencies. Further studies are required to understand the exact mechanism of action.
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Abstract
Background: Hyperuricaemia plays a significant role in the development and pathogenesis of several metabolic and systemic disorders including
metabolic syndrome, hypertension, stroke and atherosclerosis. Lycopodium clavatum is the most widely used drug in homoeopathy for treating
hyperuricaemia and gout. However, its mechanism of action in reducing serum uric acid remains uncertain. Objective: The objective of the study
was to study the potential role of homoeopathic preparation of Lycopodium clavatum in different potencies on monosodium urate crystallisation
in vitro. Methods: Spectrophotometric crystallisation assay was carried out on a stock solution of 5 ml of uric acid after its preparation. The
time course of the optical density was measured in a standard solution and values were measured every 5 min after agitation with cyclo-vortex
mixer. The optical density values were also measured in the homoeopathic preparation of Lycopodium clavatum in different potencies with same
method. Inhibiting effect of this medicine was found from graphs by measuring slope of nucleation and aggregation from optical density value
and the percentage inhibition exerted by the proteins was calculated. Results: Spectrophotometric analysis showed all potencies of Lycopodium
clavatum inhibited aggregation of monosodium urate crystals with a maximum inhibition at 200C and 1M potency. Conclusion: We found that
the homoeopathic medicine Lycopodium clavatum could be effective in inhibiting the formation of monosodium urate crystals in vitro and also
causes the dissolution of crystals, especially in high potencies. Further studies are required to understand the exact mechanism of action.
Keywords: Gout, Hyperuricaemia, In vitro, Lycopodium clavatum, Monosodium urate crystal

Introduction
Hyperuricaemia is a condition where plasma (or serum) urate
concentration is >420 umol/L (7.0 mg/dL).[1] It can result from
increased production or decreased excretion of uric acid. This
increased production is mainly due to altered purine metabolism.
Uric acid is a weak acid, so it gets ionised easily to form urates.
These urates predominate in plasma extracellular fluid and synovial
fluid. At a pH of 7.4, 98% of this urate exists as monosodium
urate.[1] When the concentration of uric acid in plasma increases,
it gets supersaturated, forming monosodium urate crystals.[1]
Deposition of these crystals results in complications such as
gouty arthritis, nephrolithiasis, urate nephropathy and uric
acid nephropathy. Hyperuricaemia has also been reported as
an independent risk factor for metabolic syndrome, obesity,
diabetes, stroke and atherosclerotic disease.[1]
The incidence of hyperuricaemia has increased dramatically
in recent decades. From 2006 to 2014, the prevalence of
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hyperuricaemia increased from 19.7% to 25.0% among men
and from 20.5% to 24.1% among women.[2]
In the stage of asymptomatic hyperuricaemia, people may not
experience any symptoms, but the crystals get deposited in
and around the joints slowly. Asymptomatic hyperuricaemia
is also a valuable biomarker for predicting the development
of cardiometabolic and renal diseases.[3]
Pharmacologic treatment for asymptomatic hyperuricaemia
carries some risks and is not considered beneficial or cost
effective and generally is not recommended. Also, there are
adverse effects and contraindications for the urate-lowering
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drugs even in acute cases.[3] Homoeopathic treatment for uric
acid, on the other hand, has no side effects and is safe to use.[4]
Febuxostat is a urate-lowering drug used frequently and this is
used as our positive control for comparing with our medicines.
An observational study was conducted on 150 diagnosed
cases of gout, where 14.67% of patients were treated
with Lycopodium clavatum. This study concluded that
homoeopathic treatment is very effective in reducing clinical
symptoms and serum uric acid levels in subjects having gout.[5]
Homoeopathic treatment is used by various homoeopathic
practitioners all over the world, but there are few studies to
show its efficiency in hyperuricaemia.
This study is an effort to prove the action of Lycopodium
clavatum on monosodium urate crystals. There are several
reports that this plant contains vanillic, coumaric, ferulic
acids and syringic acids (glycoalkaloids).[6] Further study
yielded alkaloids lycopodine as major alkaloid, clavatine and
clavatoxine; polyphenolic acids, including dihydrocaffeic and
triterpenes (Lycopodium potential).[7]

Materials and Methods
Drugs and chemicals

Homoeopathic preparations of Lycopodium clavatum[8] mother
tincture (Q), 6C, 12C, 30C, 200C, 1M and 10M) were procured
from the pharmaceutical manufacturers, SBL India Pvt. Ltd.,
New Delhi, India. All other chemicals and reagents used were
of analytical grade (Merck company, India).[9]
Three controls were taken, one of distilled water, second of
vehicle that is, rectified spirit and third of febuxostat as a
positive control.

Spectrophotometric crystallisation assay
Preparation of a 100 mg/L stock solution of uric acid

A uric acid standard solution was prepared by mixing 100 mg
uric acid in a volumetric flask. About 100 μL of 0.6 N NaOH
was added to help dissolve the uric acid. Then, pH was adjusted
to 7.4 and the solution was then made up to 1 L.[10]
It was then filtered through a 0.22 pm pore Millipore
membrane. A 5 mL of sample of uric acid stock solution was
placed into 10 mm path length cuvette holder and standard
optical density was measured using a spectrophotometer with
wavelength 300 nm. Then, values were measured every 5 min
after agitation with cyclo-vortex mixer. Spectrophotometric
crystallisation assay was also carried out for the homoeopathic
medicines using the same technique.
The time course of the optical density at 300 nm was measured
automatically using a UVIKON 930 Spectrophotometer and
values were also measured in the 100 μL of Lycopodium
(Q, 6C, 12C, 30C and 200C, 1M, 10M). Independent
experiments were conducted on each potency at least 3 times.
OD620 (optical density) increases initially during the
nucleation phase and decreases during the aggregation phase.
Slopes of the nucleation (till the maximum) and aggregation
264

(after the peak) phases were calculated using linear regression
analysis, and the percentage inhibition exerted by the proteins
was calculated using the formula:
Percentage inhibition = (1 − Sm/Sc) ×100 where, Sm is the
slope in the presence of the protein and Sc the slope of the
control.[11] This basic research followed reporting experiments
in homoeopathic basic research (REHBaR) guidelines.[12]

Results
The mean ± SE was calculated of each optical density of
different potencies after conducting independent experiments
at least 3 times.
Figure 1 shows a standard graph from the values of optical
density (O.D) obtained from spectrophotometer by keeping
solution of monosodium urate crystals without additives. An
increase in the slope of O.D indicates crystal formation and
increase in particle number and thus indicates nucleation.
After nucleation, when the solution gets saturated, equilibrium
is reached. Then, there is a decrease in O.D with time
which indicates a decrease in particle number due to crystal
aggregation. Thus, the slope of O.D with time indicates crystal
aggregations and can be used as a standard for all comparisons.
Figure 1 graph also shows the crystal inhibiting effect of
Lycopodium clavatum 6C, 12C, 30C, 200C, 1M, 10M and
control on nucleation and aggregation of crystals compared
with standard graph.
Figure 2 shows the effect of homoeopathic medicine
Lycopodium clavatum tincture and ethanol (negative control),
positive control, 200 and 1M on nucleation and aggregation
of crystals comparing with the standard graph.
Figure 3 shows that nucleation and aggregation of different
potencies of Lycopodium clavatum calculated using the
percentage inhibition formula are represented in a graph.
Here, the graph shows that all the potencies of homoeopathic
medicine Lycopodium clavatum 6C, 12C, 30C, 200C, 1M,
10M and tincture prevented the aggregation, while mother
tincture showed comparatively lesser aggregation. Maximum
inhibition was observed in 200C and 1M potencies that

Figure 1: Values of optical density of different potencies and control
compared to the standard
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studies are required to understand the exact mechanism of
action.

Figure 2: Values of optical density of the tincture, different potencies and
controls compared to the standard

This in vitro study was time-bound and we followed the
outcomes only for a few days, the results could thus be
restricted to an extent. However, since the duration of action
of Lycopodium clavatum is mentioned as 40–50 days in the
homoeopathic literature, better results can be expected on
clinical front, especially if the medicine is prescribed on
the basis of individualisation, and future studies on this
front may be considered. Further studies must be conducted
on the basis of light or electron microscopy to understand
the structure of crystals to generalise the findings that
Lycopodium clavatum can cause dissolution of crystals, thus
helping alleviating the symptoms of gout and preventing
formation of tophi.

Conclusion
Thus, in the present study, we found that the homoeopathic
medicine Lycopodium clavatum could be effective in inhibiting
the formation of monosodium urate crystals in vitro and also
causes the dissolution of crystals, especially in high potencies.
Further studies are required to understand the exact mechanism
of action.
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Figure 3: Nucleation and aggregation of Lycopodium clavatum potencies
and controls

is, they showed aggregation more than 100 similar to
the positive control. Lycopodium 1M showed very little
nucleation. This indicates that homoeopathic medicine
Lycopodium clavatum, especially 1M potency, prevents the
formation of crystals.

Discussion
Earlier, in vitro studies conducted on crystals showed the
efficiency of homoeopathic medicine, Berberis vulgaris
on calcium oxalate crystallisation and results showed that
it could prevent the early phase of crystallisation. [13] In
homoeopathy, there are many medicines known to reduce
uric acid levels, but Lycopodium clavatum is most frequently
used. A case report has shown the effect of Lycopodium
clavatum, the treatment of joint arthritis from hyperuricaemia
syndrome in birds.[14] In the present study, we found that
Lycopodium clavatum, in various potencies, is effective in
inhibiting the nucleation, which suggests that it prevents the
formation of monosodium urate crystals, and also inhibits
aggregation of crystals, thus promoting the dissolution of
crystals.
In addition, the results indicate that high potencies were
more effective than low potencies, especially 200C and 1M
potencies, which were verified by spectrophotometry. Further
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Lycopodium clavatum comme inhibiteur de la cristallisation de l'urate monosodique dans la goutte: Une étude in vitro
Contexte: L'hyperuricémie joue un rôle important dans le développement et la pathogenèse de plusieurs troubles métaboliques
et systémiques, notamment le syndrome métabolique, l'hypertension, les accidents vasculaires cérébraux et l'athérosclérose.
Lycopodium clavatum est le médicament le plus largement utilisé en homéopathie pour traiter l'hyperuricémie et la goutte.
Cependant, son mécanisme d'action dans la réduction de l'acide urique sérique reste incertain.. Objectif: L'objectif de l'étude était
d'étudier le rôle potentiel de la préparation homéopathique de Lycopodium clavatum à différentes puissances sur la cristallisation
de l'urate monosodique in vitro. Méthodes: Un test de cristallisation spectrophotométrique a été réalisé sur une solution mère
de 5 ml d'acide urique après sa préparation.. L'évolution dans le temps de la densité optique a été mesurée dans une solution
standard et les valeurs ont été mesurées toutes les 5 minutes après agitation avec un mélangeur cyclo-vortex. Les valeurs de
densité optique ont également été mesurées dans la préparation homéopathique de Lycopodium clavatum à différentes puissances
avec la même méthode.. L'effet inhibiteur de ce médicament a été déterminé à partir de graphiques en mesurant la pente de la
nucléation et de l'agrégation à partir de la valeur de la densité optique et le pourcentage d'inhibition exercé par les protéines a
été calculé.. Résultats: L'analyse spectrophotométrique a montré que toutes les puissances de Lycopodium clavatum ont inhibé
l'agrégation des cristaux d'urate monosodique avec une inhibition maximale à 200C et des puissances de 1M.. Conclusion: Nous
avons constaté que le médicament homéopathique Lycopodium clavatum pouvait être efficace pour inhiber la formation de
cristaux d'urate monosodique in vitro et également provoquer la dissolution des cristaux, en particulier à forte puissance. Des
études supplémentaires sont nécessaires pour comprendre le mécanisme d'action exact..
Lycopodium clavatum als Hemmstoff der Kristallisation von Mononatriumurat bei Gicht: Eine in vitro Studie
Hintergrund: Hyperurikämie spielt eine wichtige Rolle bei der Entwicklung und Pathogenese verschiedener Stoffwechsel- und
Systemerkrankungen wie metabolisches Syndrom, Bluthochdruck, Schlaganfall und Atherosklerose. Lycopodium clavatum ist das
in der Homöopathie am häufigsten verwendete Arzneimittel zur Behandlung von Hyperurikämie und Gicht. Sein Wirkmechanismus
bei der Senkung der Serumharnsäure ist jedoch noch unklar.. Zielsetzung: Ziel der Studie war es, die potenzielle Rolle einer
homöopathischen Zubereitung von Lycopodium clavatum in verschiedenen Potenzen auf die Kristallisation von Mononatriumurat
in vitro zu untersuchen.. Methoden: Der spektrophotometrische Kristallisationstest wurde mit einer Stammlösung von 5 ml
Harnsäure nach deren Herstellung durchgeführt. Der zeitliche Verlauf der optischen Dichte wurde in einer Standardlösung
gemessen, und die Werte wurden alle 5 Minuten nach dem Schütteln mit einem Cyclo-Vortex-Mixer gemessen. Die Werte der
optischen Dichte wurden auch in der homöopathischen Zubereitung von Lycopodium clavatum in verschiedenen Potenzen mit
derselben Methode gemessen. Die hemmende Wirkung dieses Arzneimittels wurde anhand von Diagrammen ermittelt, indem
die Steigung der Keimbildung und Aggregation anhand der optischen Dichte gemessen und die prozentuale Hemmung durch
die Proteine berechnet wurde. Ergebnisse: Die spektrophotometrische Analyse zeigte, dass alle Potenzen von Lycopodium
clavatum die Aggregation von Mononatriumuratkristallen hemmten, mit einer maximalen Hemmung bei 200C und 1M Potenzen.
Schlussfolgerung: Wir haben festgestellt, dass das homöopathische Arzneimittel Lycopodium clavatum die Bildung von
Mononatriumurat-Kristallen in vitro wirksam hemmen und auch die Auflösung der Kristalle bewirken kann, insbesondere in
hohen Potenzen. Weitere Studien sind erforderlich, um den genauen Wirkmechanismus zu verstehen..
गठिया में मोनोसोडियम यूरेट क्रिस्टलीकरण के अवरोधक के रूप में लाइकोपोडियम क्लैवेटम: एक इन विट् रो अध्ययन
पृष्ठभूमि: हाइपरयूरिसीमिया चयापचय सिंड्रोम, उच्च रक्तचाप, हृदयाघात और एथेरोस्क्लेरोसिस सहित कई चयापचय और दै हिक विकारों
के विकास और रोगजनन में महत्वपूर्ण भूमिका निभाता है । होम्योपैथी में हाइपरयूरिसीमिया और गठिया के इलाज के लिए लाइकोपोडियम
क्लैवेटम सबसे व्यापक रूप से इस्तेमाल की जाने वाली दवाई है । हालां कि, सीरम यूरिक एसिड को कम करने में इसकी कार्यप्रणाली पर
अनिश्चिता बनी हुई है । उद्दे श्य: अध्ययन का उद्दे श्य कृत्रिम परिवेश में होम्योपैथिक औषधि लाइकोपोडियम क्लैवेटम की विभिन्न पोटेंस�ियों
में मोनोसोडियम यूरेट क्रिस्टलीकरण पर संभावित भूमिका का अध्ययन करना था । विधि: इसकी तैयारी के बाद 5 मिलीलीटर यूरिक
एसिड के मूल विलयन पर स्पेक्ट्रोफोटोमेट्रि क क्रिस्टलीकरण की परख की गई। यूरिक अम्ल के बनाने के पश्चात 5 मिली. मूल विलयन पर
स्पेक्टरोफोटोमीट्रि क क्रिस्टलीकरण जां च विधि द्वारा अध्ययन किया गया। मूल विलयन को हिलाने के बाद साइक्लो-भंवर मिक्सर द्वारा
5 मिनट के अंतराल पर प्रकाशीय घनत्व को मापा गया। लाइकोपोडियम क्लैवेटम की होम्योपैथिक औषधियों की विभिन्न पोटेंस�ियों में
प्रकाशीय घनत्व को भी एक ही विधि के साथ विभिन्न शक्तियों में मापा गया था। न्यूक्लिएशन के ढलान को मापने और ऑप्टिकल घनत्व
मूल्य से एकत्रीकरण द्वारा ग्राफ से इस दवा का अवरोधक प्रभाव पाया गया और प्रोटीन द्वारा लगाए गए प्रतिशत अवरोध की गणना की गई।
परिणाम: स्पेक्ट्रोफोटोमेट्रि क विश्लेषण ने लाइकोपोडियम क्लैवेटम की सभी पोटेंस�ियों को मोनोसोडियम यूरेट क्रिस्टल के एकत्रीकरण को
200C और 1M पोटेंस�ी पर अधिकतम अवरोध के साथ दिखाया। निष्कर्ष: हमने पाया कि होम्योपैथिक दवा लाइकोपोडियम क्लैवेटम इन
विट् रो में मोनोसोडियम यूरेट क्रिस्टल के गठन को रोकने में प्रभावी हो सकती है और विशेष रूप से उच्च शक्ति में क्रिस्टल के विघटन का
कारण भी बन सकती है । कार्रवाई के सटीक तंत्र को समझने के लिए आगे के अध्ययन की आवश्यकता है ।
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Perveen, et al.: Lycopodium as an inhibitor of monosodium urate crystallisation in gout

Lycopodium clavatum como inhibidor de la cristalización del urato monosódico en la gota: Estudio in vitro
Fundamento: La hiperuricemia desempeña un papel importante en el desarrollo y la patogénesis de varios trastornos metabólicos
y sistémicos, como el síndrome metabólico, la hipertensión, el accidente cerebrovascular y la aterosclerosis. Lycopodium clavatum
es el fármaco más utilizado en la homeopatía para tratar la hiperuricemia y la gota. Sin embargo, su mecanismo de acción para
reducir el ácido úrico en suero sigue siendo incierto. Objetivo: El objetivo del estudio fue estudiar el papel potencial de la
preparación homeopática de Lycopodium clavatum en diferentes potencias sobre la cristalización in vitro del urato monosódico.
Métodos: El ensayo espectrofotométrico de cristalización se realizó sobre una solución madre de 5 ml de ácido úrico tras su
preparación. El curso temporal de la densidad óptica se midió en una solución estándar y los valores se midieron cada 5 minutos
después de la agitación con un mezclador cyclo-vórtex. Los valores de densidad óptica también se midieron en la preparación
homeopática de Lycopodium clavatum en diferentes potencias con el mismo método. El efecto inhibidor de este medicamento
se encontró a partir de gráficos midiendo la pendiente de nucleación y agregación a partir del valor de la densidad óptica y se
calculó el porcentaje de inhibición ejercido por las proteínas. Resultados: El análisis espectrofotométrico mostró todas las
potencias de Lycopodium clavatum inhibían la agregación de cristales de urato monosódico con una inhibición máxima a 200C
y 1M potencias. Conclusión: Encontramos que la medicina homeopática Lycopodium clavatum podría ser eficaz en inhibir la
formación in vitro de cristales de urato monosódico y también causar la disolución de cristales, especialmente en altas potencias.
Se requieren más estudios para comprender el mecanismo exacto de acción.
狼牙棒作为痛风患者尿酸单钠结晶的抑制剂。一项体外研究
背景介绍:高尿酸血症在一些代谢性和系统性疾病的发展和发病机制中起着重要作用，包括代谢综合征、高血压、中
风和动脉硬化。. 枸杞子 克拉瓦特是顺势疗法中最广泛使用的药物，用于治疗高尿酸血症和痛风。然而，其降低血
清尿酸的作用机制仍不确定。. 目标: 该研究的目的是研究不同药效的狼牙棒对体外尿酸单钠结晶的潜在作用。. 方
法: 分光光度法结晶测定是在制备5毫升尿酸原液后进行的. 在标准溶液中测量光密度的时间过程，用旋涡混合器搅
拌后每5分钟测量一次数值。. 用同样的方法也测量了不同药效的枸杞子克拉瓦特的同种制剂的光密度值。通过测量
光密度值的成核和聚集的斜率，从图表中发现这种药物的抑制作用，并计算出蛋白质的抑制百分比。. 结果: 分光光
度法分析显示，狼牙棒的所有效力都能抑制单钠尿酸盐晶体的聚集，在200C和1M的效力下，抑制作用最大。. 总结:
我们发现，顺势疗法药物枸杞子 克拉瓦特可以有效地抑制体外尿酸单钠晶体的形成，也可以引起晶体的溶解，特别
是在高药效下。. 需要进一步研究以了解确切的作用机制.
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